IGC Pharma Private Investor Briefing - Palo Alto

Dear Investors, We are hosting a private investor briefing with IGC Pharma (NYSE American: IGC), a clinical-stage biotechnology and AI company developing novel therapeutics and predictive intelligence platforms focused on Alzheimer’s disease. Company Overview IGC Pharma is a clinical-stage biotechnology and AI company focused on developing innovative solutions for Alzheimer’s disease. The company’s lead therapeutic candidate, IGC-AD1, is currently advancing towards a Phase 2 clinical trial topline readout targeting agitation in Alzheimer’s disease (AAD), a significant unmet need affecting millions of patients worldwide. With a topline readout from the Phase 2 (n=170) trial expected in the coming months, IGC Pharma is positioned at a potential valuation inflection of 5 to 15X from current valuations based on market peers. ​Key Highlights Phase 2 clinical trial 100% enrolled and nearing completion of dosing and database lock and topline readout. Addressing a significant unmet need in Alzheimer’s disease, a market affecting more than 40 million people globally Lead therapeutic candidate designed to improve upon limitations of current treatment options AI-powered Alzheimer’s foundation platform creating additional growth opportunities beyond therapeutics Positioned at the intersection of biotechnology, artificial intelligence, and aging-related healthcare innovation Opportunity to invest in a publicly traded company with a current valuation significantly below comparable Alzheimer's-focused biotech companies, and significantly below a positive Phase 2 readout. Event Details: Date: December 2 Time: 5:30 pm - 7:30 pm PT Location: Palo Alto, CA Please note that this meeting is for DIRECT and ACTIVE Accredited investors only. All RSVPs must be pre-registered on this site with the investor criteria filled out. All RSVPs are subject to review and approval. We will provide a confirmation email and a calendar invitation after you register. Request investor materials by contacting Skylar Rallison at [email protected]. Thanks much and all the best, Tien Wong CEO Opus8, Inc. [email protected]